Welcome to our dedicated page for Aprea Therapeutics news (Ticker: APRE), a resource for investors and traders seeking the latest updates and insights on Aprea Therapeutics stock.
Aprea Therapeutics, Inc. (Nasdaq: APRE) is a clinical-stage biopharmaceutical company developing oncology therapies that exploit specific vulnerabilities in cancer cell mutations while aiming to spare healthy tissue. News about Aprea focuses on the progress of its precision oncology pipeline, centered on DNA damage response–related targets.
The company’s updates frequently cover clinical data from its lead programs. APR-1051, an oral WEE1 kinase inhibitor, is being studied in the biomarker-focused Phase 1 ACESOT-1051 trial in advanced solid tumors. Press releases describe early signals of anti-tumor activity and disease stabilization in heavily pretreated gastrointestinal, gynecologic, and HPV-positive head and neck cancers, as well as details on dose escalation, safety, and biomarker-defined patient cohorts.
News flow also highlights ATRN-119, Aprea’s macrocyclic ATR inhibitor in the Phase 1/2a ABOYA-119 trial. The company reports identification of a recommended Phase 2 dose for once-daily dosing, early evidence of disease stabilization, and examples of tumor shrinkage in patients with DDR-related gene mutations. Recent announcements describe a strategic shift toward evaluating ATRN-119 in combination with radiation, immune checkpoint inhibitors, and antibody-drug conjugates, and the pausing of further monotherapy enrollment.
Investors following APRE news will also see regular financial results releases, updates on cash runway, private placement financings, and participation in scientific and investor conferences such as the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and the H.C. Wainwright Global Investment Conference. Together, these items provide an ongoing view of Aprea’s clinical development milestones, research collaborations, and corporate activities.
Aprea Therapeutics, Inc. (Nasdaq: APRE) announced the dosing of the first patient in its Phase 1/2a clinical trial of ATRN-119, an ATR inhibitor aimed at treating cancers with DNA damage response mutations. The trial will evaluate ATRN-119's tolerability, pharmacokinetics, and efficacy in advanced solid tumors. Preclinical studies indicate that ATRN-119 has shown potent anti-proliferative effects and the potential for lower toxicity compared to other ATR inhibitors. The company plans to share preliminary data from the trial throughout 2023.
Aprea Therapeutics (Nasdaq: APRE) reported Q3 2022 financial results, highlighting a net loss of $4.0 million ($0.12 per share), a reduction from $9.5 million ($0.45 per share) in Q3 2021. As of September 30, 2022, cash and cash equivalents totaled $33.1 million, adequate to support operations through 2023. R&D expenses dropped significantly to $1.1 million from $6.0 million year-over-year. The company is advancing its ATRN-119 clinical trial for cancer treatment, with plans to open additional sites soon.
Aprea Therapeutics (Nasdaq: APRE) announced the presentation of its abstract on the WEE1 inhibitor ATRN-W1051 at the 14th Biennial Virtual Ovarian Cancer Research Seminar Series held on September 21, 22, 28, and 29, 2022. CEO Oren Gilad highlighted ATRN-W1051's potential as a selective WEE1 inhibitor with favorable pharmacokinetic properties, showing promising anti-proliferative activity in various cancer cell lines and tumor growth inhibition in ovarian cancer models. The company plans to complete IND-enabling studies and initiate clinical programs soon.
Aprea Therapeutics (Nasdaq: APRE) announced that Oren Gilad, Ph.D., President and CEO, will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 12:30 p.m. ET. The presentation will cover Aprea’s synthetic lethality and DNA damage response (DDR) pipeline, highlighting:
- ATRN-119, a Phase 1-ready small molecule ATR inhibitor
- ATRN-W1051, a preclinical WEE1 inhibitor
- Repli-Biom, a discovery platform for precision oncology
- Eprenetapopt, a clinical-stage p53 reactivator
The presentation can be accessed on Aprea's website.
Aprea Therapeutics (Nasdaq: APRE) reported its Q2 2022 financial results, revealing a net loss of $98.3 million or $4.34 per share, significantly higher than the $10.3 million loss in Q2 2021. Cash and cash equivalents declined to $39.1 million by June 30, 2022, from $53.1 million at the end of 2021. R&D expenses remained stable at $6.8 million. The company completed the acquisition of Atrin Pharmaceuticals, heightening its focus on DNA damage response therapeutics. Upcoming clinical trials for ATRN-119 and APR-548 are expected to progress through late 2022.
Aprea Therapeutics, Inc. (Nasdaq: APRE), a Boston-based biopharmaceutical company focused on cancer therapeutics, announced that CEO Oren Gilad, Ph.D., will speak at the 2022 Wedbush PacGrow Healthcare Conference on August 9, 2022, at 12:35 p.m. ET. He will participate in a panel on synthetic lethality, hosted by Robert Driscoll, Ph.D. Aprea's lead program, ATRN-119, targets DNA damage response pathways and is Phase 1-ready for solid tumors. The company is dedicated to developing novel cancer treatments and regularly updates investors via its website.
Aprea Therapeutics, Inc. (Nasdaq: APRE) announced the acquisition of Atrin Pharmaceuticals on May 16, 2022, enhancing its oncology pipeline. The acquisition, structured as a stock-for-stock transaction, is expected to create substantial shareholder value. Aprea will focus on clinical trials for ATRN-119 and potential new therapies like ATRN-354 and ATRN-W1051. As of March 31, 2022, Aprea reported $47.6 million in cash, projected to last through mid-2023. The company saw a decrease in R&D expenses and a net loss of $7.9 million for Q1 2022.
Aprea Therapeutics (Nasdaq: APRE) reported its financial results for the year ending December 31, 2021, showing a cash balance of $53.1 million, down from $89 million in 2020. The company anticipates a cash burn of $25-$30 million in 2022, expected to fund operations into 2023. Fourth-quarter R&D expenses decreased to $4.5 million from $9.3 million a year prior, while net loss improved to $7.8 million ($0.36 per share) from $13.1 million ($0.73 per share) in Q4 2020. Aprea has received FDA clearance for new trials in myeloid malignancies and continues to advance its drug pipeline.
Aprea Therapeutics, Inc. (Nasdaq: APRE) will present a corporate update at the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, at 11:15 a.m. ET. The presentation will be led by CEO Christian S. Schade and will be available via live webcast on the company's investor relations website. Aprea focuses on developing innovative cancer therapeutics, particularly eprenetapopt, aimed at reactivating the mutant p53 protein, currently under clinical evaluation. Eprenetapopt has received multiple FDA designations.
Aprea Therapeutics (APRE) showcased promising data for its lead candidate, eprenetapopt, at the 2021 ASH Annual Meeting. Key findings include:
- 1-year relapse-free survival (RFS) of 60% and overall survival (OS) of 79% in a trial involving post-transplant patients.
- A 69% overall response rate (ORR) and 43% complete response (CR) in patients with TP53 mutant MDS/AML.
- 64% ORR with 39% CR in patients treated with a combination of eprenetapopt, venetoclax, and azacitidine.
The data indicate the treatment is well-tolerated across trials.